

































































































































































































BV  HV  CP  CG 
Cardiac muscle          
Heart valve          











         
         
         
         










BV  HV  CP  CG 
           
           
           
           
           
           
           
           
2.2.2. Animal cell lines 
Specify Lineage  Comments  Bioreactor allocation 
BV  HV  CP  CG 
           
           
           
           
           
           
           
           
 









BV  HV  CP  CG 
Scaffold 1:           
Scaffold 2:           
Scaffold 3:           
Scaffold 4:           
Scaffold 5:           
Scaffold 6:           
Scaffold 7:           
Scaffold 8:           









BV  HV  CP  CG 
Mechanical           
Electrical           
Fluidic           
           
Others (Specify):           
           
           
           
           
 
Culture media handling  Comments  Bioreactor Type 
BV  HV  CP  CG 
Seeding:           
‐  Static culture medium           
‐ Perfusion           
‐ Air/media interface           
Culture phase:           
‐ Static culture medium           
‐ Perfusion           










BV  HV  CP  CG 
Peak force [N]                    or       Stress [MPa]              
Max. Elongation [mm]          or            Strain [%]           
Frequency of stimulation (Hz):         
Other (specify): 
 
       
         
 
Electrical Parameter  Range (± accuracy) 









BV  HV  CP  CG 
Flow [mm3/s]         
Pressure [Pa]         
Other (specify): 
 
       
         
 







BV  HV  CP  CG 
         
         





BV  HV  CP  CG 
Temperature          
Dissolved CO2 [Pa]         
Dissolved O2 [Pa]         
Glucose rate [mol/ml]         
Lactate Rate [mol/ml]         
Ammonia rate [mol/ml]         
Glutamine Rate [mol/ml]         







BV  HV  CP  CG 
Type of sterilization (Specify): 
 
       
Maximum temperature tolerable [°C]         
Maximum humidity [%]         













BV  HV  CP  CG 






































BV  HV  CP  CG 
Displacement graphic control 
 
         
Load graphic control 
 




































-  Use of a  roller pump and modulated RC circuit  for  the generation of pulsatile  regimen of  radial 
strain and shear stress (variation of the compliance/resistance/pinch valve configuration allows to 
vary phase relationship between pressure and flow through the graft).  



















































































‐       Rotating culture bioreactors    (RCBs) combine high mass transport rates with very  low shear force     
       (1  dyne/cm2)  ,  in  conjunction  with  predominately  laminar  flow  conditions.  
    
- RCBs  can  be  used  to  culture  cells  to  assess  the  ability  of  the  implemented  gel  to  favor  cell 
bioprocessing  
      ‐       Cell can be directly encapsulated within gel micro carriers  to evaluate cell growth/ differentiation  
             (A.2) 





































































In order to reach its customers and targets, Biomicron CED’s marketing strategies will envisage public 
relations, articles in specialised magazines, technical workshops, seminars, scientific congresses, public 
meetings and promotions with both research centres and hospitals. A website will also be created to 
publicise the business activity and a campaign of direct contacts with the research centre and hospital 
laboratories is envisaged, all with the main aim of developing awareness of the products and knowledge of 
the company.  All the activities following production (purchase, delivery, after-sales service) will initially be 
pursued through direct contacts between the staff of Biomicron CED and customers.  
 
Customer Relationship 
The company intends to offer direct personal service to buyers, in keeping with the aim of setting up a stable 
relationship with them. In particular, the idea is to offer a more effective after-sales service than the 
competition, installing the product at the buyer’s premises, training staff in the use of the device and 
withdrawal/exchange of the used product.  
 
Customer Segment 
Adapting its methods and timing, the company intends to approach two main market segments: hospitals and 
research structures, considering the second category to be an articulated combination of red biotech 
companies, research centres and IRCCS (Institute of Scientific Recovery and Care). 
 
Revenues 
Biomicron CED’s main revenue stream comes from the direct sale of its product to the end customer. The 
royalties from the sale of specific disposables will represent a source of parallel revenues capable also of 
encouraging the continuity of a relationship (indirect) with the customer. The company also intends to offer 
its technical know-how for the planning of upgrades or new bio-reactors to suit customer requirements. This 
activity, which was initially performed by entrepreneurs, will generate revenues in the form of technical 
consulting in relation to the products.  
 
Key Resources 
The first fundamental resource identified consists of the specific capacities of the design, assembly, 
maintenance and servicing staff. The skills of staff must be suited to the construction of a product like the 
bio-reactor, and must therefore combine sensitivity towards medical-clinical issues and technical skills. A 
second key resource will be intellectual property, given that every effort will be made to protect some of the 
technical solution with patents.  
 
Key Activities 
The future company will concentrate on the phases of concept/design of the product in all its 
components (main and accessory) and on those of product marketing. Other activities central to the 
business strategy will be assembly (which for a product as innovative as that in question is a critical 
and complex activity) and after-sales assistance for customers.  
 
Key Partners 
The company will make use of a fundamental cooperation with Biomicron Srl, which also cover the financer 
of the start-up, holding part of the company shares. This partner will take care of production and the 
complementary procurement activity, offering useful references for marketing, as well as legal and 
accounting aspects. The suppliers of the other components (actuators, sensors, etc.) will however be 
fundamental to ensure that the product conforms to market requirements. 
 
Cost Structure 
The company’s cost structure will be initially centred on variable costs, i.e.: the costs linked to the 
production of the bioreactor, trying to reduce sunk costs which could limit the company’s flexibility and 
worsen the initial lack of available funds. This cost saving activity will be accomplished thanks to 
cooperation with Turin Polytechnic, which will offer the premises to house the activity, at a commercial 
price, and to the partner Biomicron Srl which will offer the same service from the fourth year onward. 
 
Value Proposition 
The Biomicron CED proposition intends to match technological innovation and a competitive price. The 
first component in particular will be embodied by a device that simplifies the job of the operators, automate 
the processes, improve the quality of the results and guarantee very flexible use. Vice versa, the reduced cost 
will allow access to the technology in question to those organisations that are interested but have limited 














(*)  the  term user  refers  to a customer who,  in his business activity, has already used a bioreactor and decides  to 













LVDT linear actuators 
capable of reaching high 
power and speed 
 
Process automation and increased 
quality standards 
 
Better results and time 
saving to perform 




Systems for grafting and 
ungrafting the culture 
chamber from the other 
components 
 
Bioreactor capable of using several 
types of tissue 
Multi-chamber 
Reduction of the risks of 
contamination 
 
Reduction of purchase 
costs (10-50%) 
 
Reduction of time to 
result 
 






and more reliable 
results 
 
Electronics for checking 
parameters and processes in 
a closed loop through 
dedicated circuits on 
microchip 
 
Process automation and increased 
quality standards 
 
Less operator stress and fewer human errors 
 




Simple, customised software 
package. 
Possibility to manage the culture 
parameters automatically, using 
software, without intervening 
directly in the culture chamber. 
 
Better understanding of the results and easy use 
by users with less experience. 
 
Time savings (better with automatic 
management), reduced contamination risks, use 
by users with less experience. 
 
ANNEX IV – Analysis of questionnaires 
The questionnaires sent have the following structure: 
 








The answers received are listed below: 
 
Structure of origin        Percentage
   Private Research Centre  2  11%
   Hospital Structure  1  5%
   University  13  68%
   Public Research Public  3  16%
 
Professional Role        Percentage
   Researcher‐teacher  1  5%
   Biologist  6  32%
   Bioengineer  2  11%
   Research Doctor  3  16%
   Biotechnologist  3  16%
   Immunologist  3  16%





Sterilisation methods        Percentage
   Steam autoclave  18  95%
   Etox  1  5%
   UV Ray  7  37%
   Dry sterilisation  5  26%
   Gamma rays  1  5%
 
Budget        Percentage
   < 50,000  6  32%
   50,000‐500,000  1  5%
   50,000‐300,000  10  53%
   > 1000000  1  5%
   Don’t know  1  5%
 
Cells used        Percentage
   animals  16 84%
   human  15 79%
 
 
Importance of the risk of contamination 
high  medium  low 
Insemination 
phase  5  6 8 
 
high  medium  low 




phase  5  8 6 
 
Number of tissues used        Percentage
   Only 1  3  16%
   From 2 to 5  12  63%



















Cardiac    3 16%
Bone    8 42%
Nerve    4 21%
Cartilage    1 5%
Vascular    4 21%
Epithelial    6 33%
Tumour cell plasma  1 5%
Embryonic    1 5%
Muscle    3 16%
Ovarian‐testicular    1 5%




Structure with a bioreactor        Percentage
   yes  8   42%
   no  11   58%
 
Link with the bioreactor        Percentage
   Known and used  7   37%
   Known but not used  9   47%
   Unknown  3   16%
 
Interest in customised software           Percentage
   yes  5   71%
   no  2    29%
 
Additional services for those who use a bioreactor 
  Have it and am interested Don’t have it but am interested  Not interested
Installation and staff training  5 2  0
 
  Have it and am interested Don’t have it but am interested  Not interested



















Functional importance for those who know and use the bioreactor  
 
  Fundamental  Very important  Quite important
Not very 
important  Not important
Administration  1  3  3  1  0 
 
 
Fundamental  Very important  Quite important Not very 
important  Not important
Automation  0  4  4  0  0 
 




































customisation         
Systems for grafting and ungrafting the culture 
chamber from the other components  Multi‐tissue Bioreactor       n/a   
Use of disposables for some components  Reduction of the risk of 
contamination         
Electronics for checking parameters  Ease of use and 
customisation         
External incubator unnecessary  Versatility         
High versatility (adaptability to tissues suitable for 
cultivation in traction and compression)  Versatility      n/a   
Easy scalability (expendable up to 12 chamber 
cultures)   Versatility         
Access to the culture chamber from above (easy 
access)  Ease of use         
Optic access for phase contrast microscope  Versatility         
Easy opening and closing of the chamber without the 
use of instruments  Ease of use         
Possibility to install the samples outside the culture 
chamber  Versatility      n/a   
High frequency mechanical stimulation  Versatility      n/a   
Peak force above 600N  Versatility      n/a   
Maximum force during culture cycles up to 400N  Versatility      n/a   
Maximum amplitude of mechanical stimulation up to 
5 mm  Versatility      n/a   
Adjustment of the perfusion capacity  Versatility         
Adjustments of the perfusion capacity on a broad 
range (from 0.1mL/min to 500mL/min)  Versatility         
Possibility for electrical stimulation  Versatility      
Gas expansion module to minimise air bubbles in 
culture fluid  Versatility 
    
User interface in a single window  Ease of use      
Automatic management of the culture from 
insemination to removal  Ease of use 
    
 










































 Number of companies: currently 19; these include 3 major brands (Bose ElectroForce, TGT and 
Synthecon).  
 Reputation (brand identity): Bose ElectroForce is a consolidated and well known brand. The other 
competitors, while not yet having a solid reputation, have good possibilities of this becoming 
consolidated in the future.  
 Switching costs for buyers (product): there are no relevant switching costs, because for other instruments 
linked to the use of bioreactors, such as incubators, scaffolds and laboratory instruments are not 
restricted to the model in use. The switching costs will tend to rise insofar as there will be greater 
attention paid to connected services. Internal rivalry will decrease. 
 Exit barriers: The facilities aren’t dedicated solely to the production of bioreactors, but can also be used 
for other purposes (there are no high costs for conversion of the production facilities). This means that 
there are no large exit barriers.  
 Product standardisation: different tissues correspond to different products; all the other features such as 
single chamber/multi-chamber, disposable/non-disposable, modular/non-modular, etc… mean that the 
product is differentiated. This is confirmed by the absence of a dominant bioreactor design. Furthermore, 
it is a product purchased by those specialised in the sector, who don’t see it as a standard product. 
 Transaction frequency: the average life of a bioreactor is about 4-5 years. 
 Informative complexity of the transactions: complex transactions, even when carried out by specialised 
buyers who reduce the informative asymmetry. Moreover, the specific features of the bioreactor and the 
production process aren’t all that clear, not even to experts. 
 Growth rate in the sector: the biotechnologies sector, particularly red biotech, is growing mainly in 
Europe and the emerging countries. The growth rate is 5-6% in Europe and 15% in the emerging 
countries. 
 





 Economies of scale: current production volumes are low and bioreactors are not standard products, so 
there are no big economies of scale. There could be greater economies of scale in the production of 
disposables. 
 Economies of scope: medium-low economies of scope, because in adjacent sectors the products of 
incubators, centrifuges, fermenters, etc., which do not fully share the same machinery and the same 
skills, are considered. 
 Difficulty in accessing human resources: professional figures in the biomedical field who have matured 
specific know-how and experience in the bioreactor sector are not easy to find, as they combine 
technological and design aspects with biological knowledge.   
 Control of businesses in the sector operating in raw materials and distribution channels: as the market 
guarantees and extensive offer and free access to raw materials and the components required for the 
production of bioreactors, there is no difficulty in finding them. As regards distribution channels, 
however, there could be greater complications with access to certain foreign markets, particularly the 
emerging markets. 
 Economies of learning: the production of bioreactors is complex to achieve because it requires both 
technical skills an sensitivity towards the field of biotechnologies and the relative problems. 
Consequently, it is a “learn-by-doing” and this creates a considerably barrier towards entry.  
 External positioning of networks:  these do not create a barrier because external positioning is very 
infrequent. This is justified by the fact that the purchase of a bioreactor by a user does not encourage 
another user to purchase it and the value perceived by the buyer is generated entirely by the intrinsic 
value of the product. There is no need to reach a critical mass and at the moment there are no 
consolidated technological standards. 
 Presence of intellectual property: patents are an obstacle to entry, insofar as they are multiple, both in 
relation to product and process. 
 Brand loyalty: the judgement is consequential to that claimed with regard to switching costs and in 
relation to the importance of services (after-sales service, maintenance, etc.) in creating brand loyalty. 
 Government and legal barriers: there is no need for government permits to produce bioreactors.  
 Threat of retaliation by competitors (incumbent):  in the short term, the main threat will be linked to 
spin-offs similar to Biomicron CED; while in the long term, it is thought that the main obstacles will be 
created by consolidated competitors.  
 
GLOBAL JUDGMENT – Entry barriers: MEDIUM-LOW 
 
 
Power of suppliers 
 
 Number of suppliers: the raw materials purchased by those who produce bioreactors are commodities 
that can easily be found by a large number of suppliers; the same goes for components such as pumps, 
sensors and linear actuators, despite these being more specific for bioreactors. Even where the 
percentage of purchases from the same supplier is considerable, there is an awareness by the customer 
and the supplier of the wide variety of rival suppliers who can guarantee the same resources.  
 Differentiation of supplier product: in general, all the input used is quite standard and undifferentiated, 
although sensors and certain more specific components can present major peculiarities that lead to a 
“medium-low” rather than “low” judgement. 
 Switching costs for the producers of bioreactors: these costs are low but not non-existent, insofar as there 
can be early terminations of contracts and diseconomies linked to the fact that the new supplier might not 
agree to the same conditions and discounts. 
 Threat of subsequent integrations: the threat of integration of suppliers is unlikely and therefore of little 
importance. 
 Cost saving deriving from the purchase of components from specific suppliers: in general, the low 
differentiation of the components used implicates a low differentiation of price, which translates into 
lower potential savings in passing from one supplier to another. 
 Importance of the quality of the components of specific suppliers: the quality of the components is in 
actual fact important, but there isn’t much difference in quality between suppliers. Consequently, the 
impact of this factor is limited in the judgement on the power of suppliers.       
 Cost of the components of suppliers in relation to the total cost of producers: the main cost categories 
are: research and development, production, marketing and any accessory after-sale costs. Despite not 
being negligible, the cost of certain specific components in relation to the production cost, their weight in 
relation to the total cost is limited, reducing the power of the suppliers.  
 
GLOBAL JUDGMENT – Power of suppliers: LOW. 
 
 
Power of Customers 
 Threat of integrations: the threat of integration of customers is unlikely and therefore of little importance. 
As stated earlier, the production of a bioreactor is complex because it requires technical skills and 
sensitivity, particularly in terms of mechanical design, and these skills are not possessed by biology 
experts. 
 Switching costs for customers: there are no relevant switching costs, because other instruments 
connected to the use of bioreactors, such as incubators, scaffolds and laboratory instruments are not 
restricted to the model in use.  
 Volume of purchase by the same customer: it is more likely that there will be a large number of 
customers who buy just a few bioreactors at a time than a small number of customers who buy lots of 
bioreactors. 
 Differentiation of manufacturer product: different tissues correspond to different products; all the other 
features such as single chamber/multi-chamber, disposable/non-disposable, modular/non-modular, etc… 
mean that the product is differentiated. This is confirmed by the absence of a dominant bioreactor design. 
Furthermore, it is a product purchased by those specialised in the sector, who don’t see it as a standard 
product. 
 




Bioreactors can be replaced by the traditional in vitro cell culture. 
If we consider the use of bioreactors also for transplants, then the traditional transplant and artificial 
products (e.g.: heart valves, etc.) are also potential substitutes. 
To calculate the level of suitability as a substitute, the current and future situations in terms of bioreactor 
market development were taken into account:  
 
Present: 
1. MEDIUM-HIGH substitution of in vitro cell culture, because bioreactors are an “evolution” for 
specific needs with respect to traditional culture; 
2. LOW substitution of in vivo cell culture, because the tests cannot be carried out on people (in vivo 
culture envisages the development of the tissue directly on people). 
 
Future: 
1. LOW substitution of in vitro cell culture, because the latter is not very well suited to this type of use; 
2. HIGH substitution of in vivo cell culture, because both develop tissues destined for transplant, with the 
difference of the extension of the tissue outside or inside the body. While suitability for substitution 
increases, the complementary aspects also increase, because bioreactors would be used to carry out in 
vivo pre-transplant tests and for parallel monitoring. 
Generally-speaking (based upon research carried out and questionnaires analysed) we can conclude that 
many researchers would be interested in working in the field of regenerative medicine with bioreactors, 
because they allow more automated culture which reduces human intervention in certain phases and, 
consequently, the risk of human error and contamination. The only variable that influences the rate of 
substitution is the price of the bioreactor. 
 



































                                                                                                              
FIRST PRODUCT DEVELOPMENT 
                                                                                                 





                                                                                            
                 
PATENTING (FOR 2‐3 YEARS)
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To observe the entry aims, the strategic activities to be implemented are:  
 
SHORT-term aims  MID-term aims  LONG-term aims 
Communicate the product (the VP) to a 
certain number of potential Italian 
customers to create the first future 
contacts.  
Growth of product awareness among 
potential customers in Italy and abroad.
Creation of brand 
awareness 
 
Short Term: during this period of time, the company proposes to communicate and publicise its value 
proposition to potential future customers. The main activity will be to create the first contacts with future 
buyers to show the innovation related to the product and to reassure them of the quality of the bioreactor and 
of the company. 
Mid-Long Term: having begun the product industrialisation phase, the company will have to continue 
investing considerable resources to further increase customer awareness, and other resources will be 
necessary to develop technological innovation in such a way as to maintain distance from competitors. 
Product awareness is vital for a company which has just entered the market, much more so than brand 
awareness to which the company will dedicate resources later. Biomicron CED will focus its resources on a 
specific model of product (bioreactor for cardiovascular tissue) and only later will it expand its range of 
products with new models. 
Long Term: the company will invest its resources in brand awareness and, above all, in what is described as 
“brand quality”. The main aim of the entrepreneurs is to make the name Biomicron CED synonymous with 
the product and the reliability of the results, insofar as it will be used in the biomedical sphere. A second aim 
will be that of transforming a push type distribution strategy into a pull type strategy, meaning that 
Biomicron CED will have to exploit previous investments to expand its contacts with customers and for 
development of the brand, so that the end customer will contact the company and not vice versa. A third aim 
will be to create new product models for different tissues, in order to differentiate the product and expand 
market demand. 
In general, we need to remember that the characteristics of the high technology sector in question lead to the 
consideration of the brand identity factor as relatively unimportant, in the short term, when it is possible that 
the characteristics of the product may carry more weight than the brand. Vice versa, looking at things in the 
long term, the company could imagine being able to “induce” brand identity in a market where, at the 
moment, it seems to have little influence, acting as provider of services and creating customer loyalty by 











 S-O Strategies: 
 Exploit the experience and consolidated know-how of entrepreneurs, the high technological content 
and the extensive offer of services, to focus the strategy of satisfying the needs of users, filling the 
gap between demand and supply. 
For example, the sale could be accompanied by the disbursement of cell culture assistance or product 
customisation options could be offered to suit requirements.  
 Speed up the growth of the company on the market, exploiting the partnership with Biomicron Srl 
and the absence of a dominant design. 
 Increase communication, emphasising the good price-quality ratio and the positioning as a niche 
product, to tackle the albeit limited number of competitors who are already consolidated. (e.g.: 
presence at trade fairs, announcements in specialised magazines, on websites, etc.). 
 
 S-T Strategies: 
 Patent Biomicron CED solutions and technologies with the aim of protecting them from any 
substitute technologies by competitors already consolidated on the market.  
 Exploit the partnership with Biomicron Srl, cooperating in sourcing key resources and implementing 
a raw material cost sharing policy. 
 Exploit in-house assembly to develop more control over the finished product, checking its 
distribution and inimitability by competitors. 
 Participation as shareholder of Biomicron Srl to mitigate the risks deriving from the presence of a single 
supplier for ad hoc components.  
 
 W-O Strategies: 
 Exploit the vicinity with the academic world and set up further cooperations with special structures 
for start-up (university incubators), trying to source research funds to cover the initial investments in 
R&D. 
 Implement policies aimed at maintaining lasting relationships with customers, to obtain a broad basin 
of loyal customers with a desire to cooperate. In this way it is possible to speed up entry to market 
and the relative time to market, also making up for the lack of knowledge of the business world by 
entrepreneurs. 
 
 W-T Strategies: 
 Reduce the time to market to cope with the development of substitute technologies and imitations by 
competitors (advantage of quick implementation in research centres). For example, if the product is 
introduced quickly into research centres, scientists will study and operate exclusively on Biomicron 
bioreactors, with a consequent very high switch-off cost to rival technologies. 
 Activate several partnerships and outside cooperations (with Biomicron Srl, University research 
centres, etc.), to make up for the lack of knowledge of the business world and have more funds to 





Customer acquisition process 
Phases/activities Operating levers Activities and resources 
Sourcing of 
suppliers/manufacturers 
Customer must know Biomicron CED as 
a supplier of bioreactors 




Publicise products, prompt response to 
requests for information or an estimate 
Commercial operators and planners 
available also on secondment and capable 
of quickly meeting the needs of 





Remain at the customer’s disposal to 
provide any additional information 
Commercial operators and planners 
available  
(Request for demo + 
demo) 
Need for a functioning product available 
on trial 
Planner + commercial operator 
Prototype, means of transport, PC and 
software 
Final assessment and 
choice 
Remain at the customer’s disposal to 
provide any additional information and 
levers to convince them 
Commercial operators and planners 
available  
The commercial manager could also 
contact the customer 
(Possible in-house 
contracting within the 
purchase authorisation 
centre) 
Offering information and simple 
prospects regarding product convenience 
 
Negotiation Willingness to make amendments to the 
contracts – price negotiation 
Complete standard contract 
Commercial operator and planner 
Signing the Contract   
Product delivery Timing in line with that established, 
making the customer aware of timing and 
willingness to provide assistance 
All assembly, packaging and shipping 
activities are necessary 
 
 
Qualitative assessment of the promotional activities 
 
Activity Total cost Use of BM 
CED staff 
Total duration Reaching (Number - 
Target) 
Participation in trade fairs A A B A -MS 
Website MA B B A - PS 
Demos MA MA A B - MS 
Free test culture A B A B - MS 
Adverts in specialised magazines MA B MA A - S 
Public relations MB MB MB MB - S 
 
 
the term “Total cost” means the total expenditure needed to perform the activity in question 
the term “Use of BM CED staff” means the need to use in-house staff and the consequent impossibility to offer the 
activity in question through outsourcing for example 
the term “Total duration” means the whole time between the start and the end of the activity in question 
the term “Reaching” means the number of people or organisations reached with that activity and the type of people or 
organisations reached (target specifics) 
A = "High", MA = "Medium-High", MB = "Medium-Low", B = "Low"; MS = "Very Specific", S = "Specific", PS = 




Promotional activity cost estimate 
Activity Cost* 
Participation in trade fairs 73.000 € 
Website creation 2.000 € 
Website fee 1.000 € 
Adverts in specialised magazines 11.000 € 
Public relations** 6.200 € 
 
* the cost refers to the performance of activities throughout the term of the business plan (5 years). 
** in assessing this item, reference is made to the publication of scientific articles and the to the purchase of 
promotional material, consequently supplying a lower estimate.  
Note: the test culture and demo costs will not be explicitly calculated as these activities will be included in the broader 
context of the tasks assigned to the commercial staff and their cost may vary considerably depending on the type and 








 Production: 6 working days 
Core competencies of Biomicron CED are the design and assembly of the bioreactors. The actual 
production, envisaged from the 3rd year of business following the incorporation of the company, will be 
outsourced to Biomicron Srl, also based in Turin. The latter will be responsible for the transformation of raw 
materials and unfinished products (which it will order from its supplier network) into finished products. The 
delivery of these pieces will be regulated by contract and will take place within 6 working days of the order.   
 
 Quality control on input supplies: 4 hours 
The check to ensure that the supplies work properly and are free from defects is a particularly important 
activity for Biomicron CED as the bioreactor to be manufactured will be extremely delicate and precise in its 
measurement and stimulation of the tissue. For this reason, defective components could lead to distorted 
measurements and imprecisions which would convey a negative image to the company. Initially, the quality 
control will be managed directly by a member of the business team.  
 
 Assembly: 12 hours 
The assembly activity will be manual and will require the equipment used typically in a mechanical 
workshop. The products ordered from Biomicron Srl will be assembled with the other components 
(actuators, sensors, etc.). A modest sized warehouse, situated at the production premises of Biomicron Srl, 
will be destined for storing only those components purchased by Biomicron CED from third parties. In this 
way, Biomicron CED will succeed in guaranteeing its customer delivery of the product within 14 working 
days of receipt of the order, which corresponds to 18-20 calendar days. Alternatively, we could assess the 
possibility of having no stocks, for two main reasons: firstly, to avoid slow movement of stock and therefore 
of cash, which are hard for a company just starting up to sustain; secondly, to guarantee greater flexibility if 
the customer requires specific components (e.g.: of a specific brand). Naturally this option will implicate 
longer delivery times. 
In the immediate term, it will not be necessary to employ assembly staff, because the activity will be carried 
out by members of the team. These will only be required later.  
 
 Finished product quality control: 8 hours 
The finished product quality control will implicate ensuring that all the components have been properly 
assembled and that there are no functional defects in the bioreactor made. Lastly, tests will be carried out on 
the controls and mechanical functions performed by the future assembly staff. 
 
 Packaging: 3 hours 







T=0  T=6  T=10  T=14 
Acquisition of the order by the customer  X       
Issue of the order to Biomicron Srl  X       
Arrival of component to be assembled    X     
Product ready for delivery      X   



























































Premises I3P     
YEAR I:  11,110 € (for fee, services and activation) + 3,600 € (forfeit for use of Polytechnic premises) 
YEAR II:  11,350 € (for fee and services) + 3,600 € (forfeit for use of Polytechnic premises) 
YEAR III:  13,900 € (for fee and services) + 3,600 € (forfeit for use of Polytechnic premises) 
 
At Biomicron Srl  
FROM YEAR IV:  5,400 €  
 
The decision to use premises 13P in the first few years follows careful assessment of a series of possible 
benefits, such as: 
- network, i.e.: contact with new businesses, possible partners, knowledge and cooperation with  
  companies with considerable growth prospects; 
- managerial support which favours the launch of the business activity; 

















2-3 days (also at the same time as the previous phase)
 




(Request for demo + demo) 
 
0 time for request + appointment in 3-10 days + demo (1 day)
 



















From the dispatch of the finished, packaged product, about 2 days 
in Northern Italy; 3 days to Central Italy; 4-5 days to Southern 





Between 4 – 10 weeks for the most complex transactions 





In the European context, EC Regulation 1394/2007 is the standard, along with the other three EC Directives  
2004/23, 2006/17 and 2006/86 (which regulate, among other things, the procurement, control and processes 
of human cells and tissues).  
 
Propositions to improve the authorisation process for clinical studies 
The process for the authorisation of drugs for gene therapy, somatic cell therapy and tissue engineering is 
influenced by all the limits that we already know about, connected with the complexity of the documentation 
to be supplied for traditional drugs, with the added weight of chronic delays in the procedure for the 
authorisation of study.  
Considering that the new pre-clinical and clinical models, which are specific to tissue engineering, are still 
undergoing debate and standardisation at European and national level, it would be appropriate to: 
 formalise the creation of a “pre-submission meeting” with the pertinent organisation (ISS/AIFA), 
which provides assistance/advice in the phase prior to presentation of the application for clinical 
testing, at least 6-12 months in advance;  
 set up a national advisory service during the subsequent clinical development (Phases II and III). This 
would create a “bridge” between the proponent and the EMA/CAT which could show the company a 
way to carry out clinical studies and allow the Italian representatives within the CAT to report the 
problems encountered at local level, fitting them into a broader process of assessment. 
If flanked by more efficient communication and interaction between industry and institutions, these paths 
could lead to greater clarity with regard to the suitability of the documentation, in support of the request for 
authorisation, and to the streamlining of the procedure with reduced times and costs.   
 
Exclusions from the registration procedure (art. 28) 
It is necessary for the Italian authority to define exactly the criteria and requirements according to which the 
products must be considered as “prepared on a non-routine basis”. Indeed, the setting of clear and objective 
criteria for the definition of these products would avoid the need to apply different rules to the public and 
private sectors, with an improper use of article 28 by certain structures, which – despite pursuing 
manufacturing activities within the GMP context, could manufacture products destined for human use 
without this implicating the obligation to have an AIC (authorisation for release for sale) issued by the EMA. 
 
Use of drugs after the transition period 
Given the current uncertainty with regard to standards and interpretation, the AIFA (Italian Drug 
Association) should supply clarification for drugs marketed in Italy with regard to the requirements needed 
to define the meaning of “legally on the market”. Furthermore, in view of the considerations already made 
on the reduced number of applications for AIC (authorisation for release for sale) presented, to prevent 
patients from being left without adequate therapy at the end of the “transitory” period, it is important for the 
possibility to continue using such drugs to be explicitly envisaged if there are documented activities in 
support of the application for authorisation for  release for sale and there is no drug approved according to 
EC regulation 1394/2007. To this end it would be appropriate for the AIFA (Italian Drug Association) to 
promote this stance with the European Commission, to guarantee continuity of access to these therapies. As 
well as defending patients, this would encourage companies to continue investing in the search for new 
therapies within the sphere of biomedicine. 
 
Requirements for exporting to Italy 
In addition to the critical issues already mentioned, the use of tissue engineering gene therapy drugs 
imported from EU countries should be considered. For obvious ethic and public health-related reasons, 
during the transitory period, these drugs should be subjected to the same criteria in terms of quality and 
safety already defined for those produced in Italy. 
Therefore, the production of these imported drugs must be carried out in conformity to the GMP, with 
particular regard also to the grading of the materials and the quality of the finished products, and the AIFA 
(Italian Drug Association) must certify that they fall within the scope of article 29 of EC Regulation 
1394/2007. 







































    Profit and Loss  
    Time span – 5 years 
Euro    Year 1           Year 2           Year 3   Year 4   Year 5   


























































 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
48.000  
 €        
-    
 €        
-    
 €        
48.000  
 €        
48.000  
 €        
264.000  
 €        
396.000  
 €        
726.000  
 €        
924.000  
 €        
1.584.000  
 €        
1.716.000  
Disposables 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
9,60  
 €        
9,60  
 €        
9,60  
 €        
19,20  
 €        
28,80  
 €        
201,60  
 €        
374,40  
 €        
691,20  
 €        
1.094,40  
 €        
1.785,60  





 €        
-    
 €        
-    
 €        
-    
 €        
9.600  
 €        
9.600  
 €        
9.600  
 €        
5.760  
 €        
5.760  
 €        
5.760  
 €        
5.760  
 €        
5.760  
 €        
5.760  
 €        
27.840  
 €        
33.600  
 €        
57.024  
 €        
91.968  
 €        
151.872  
 €        
216.768  
Total 
 €        
-    
 €        
-    
 €        
-    
 €        
9.600  
 €        
9.600  
 €        
9.600  
 €        
5.760  
 €        
53.770  
 €        
5.770  
 €        
5.770  
 €        
53.779  
 €        
53.789  
 €        
292.042  
 €        
429.974  
 €        
783.715  
 €       
1.017.062  
 €        
1.737.658  
 €        
1.935.302  
     
COST OF 
SALES             
Product Costs 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
22.110  
 €        
-    
 €        
-    
 €        
22.110  
 €        
22.110  
 €        
99.000  
 €        
148.500  
 €        
272.250  
 €        
346.500  
 €        
594.000  




 €        
-    
 €        
-    
 €        
-    
 €        
3.600  
 €        
3.600  
 €        
3.600  
 €        
2.160  
 €        
2.160  
 €        
2.160  
 €        
2.160  
 €        
2.160  
 €        
2.160  
 €        
9.960  
 €        
11.400  
 €        
18.864  
 €        
30.288  
 €        
84.432  





 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
10.200  
 €        
10.200  
 €        
10.200  
 €        
10.200  
 €        
10.200  




 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
484  
 €        
1.211  
 €        
2.543  
 €        
4.239  
 €        
6.661  
 €        
9.083  
Total 
 €        
-    
 €        
-    
 €        
-    
 €        
3.600  
 €        
3.600  
 €        
3.600  
 €        
2.160  
 €        
24.270  
 €        
2.160  
 €        
2.160  
 €        
24.270  
 €        
24.270  
 €        
119.644  
 €        
171.311  
 €        
303.857  
 €        
391.227  
 €        
695.293  
 €        
859.991  
     
 GROSS 
PROFIT     
 €       
-    
 €       
-    
 €       
-    
 €       
6.000  
 €        
6.000  
 €       
6.000  
 €       
3.600  
 €       
29.500  
 €       
3.610  
 €       
3.610  
 €        
29.509  
 €       
29.519  
 €        
172.397  
 €        
258.663  
 €        
479.858  
 €        
625.836  
 €        
1.042.365  
 €        
1.075.311  
     




 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
10.200  
 €        
10.200  
 €        
10.200  
 €        
10.200  
 €        
10.200  
 €        
20.400  





 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
300  
 €        
-    
 €        
300  
 €        
-    
 €        
300  
 €        
-    
 €        
1.000  
 €        
1.000  
 €        
1.000  
 €        
1.000  
 €        
1.250  
 €        
1.250  
                  
Research and 
Development             
 Material 
 €        
337  
 €        
674  
 €        
674  
 €        
1.012  
 €        
1.349  
 €        
1.349  
 €        
1.686  
 €        
2.023  
 €        
2.023  
 €        
2.361  
 €        
2.698  
 €        
2.698  
 €        
10.117  
 €        
12.140  
 €        
12.140  
 €        
12.140  
 €        
12.140  
 €        
12.140  
 Services 
 €        
203  
 €        
406  
 €        
406  
 €        
608  
 €        
1.367  
 €        
1.367  
 €        
1.569  
 €        
1.772  
 €        
1.772  
 €        
1.975  
 €        
2.733  
 €        
2.733  
 €        
9.417  
 €        
12.300  
 €        
12.300  
 €        
12.300  
 €        
12.300  
 €        
10.633  
 Labour 
 €        
322  
 €        
833  
 €        
1.344  
 €        
1.856  
 €        
2.367  
 €        
2.878  
 €        
3.389  
 €        
3.900  
 €        
4.411  
 €        
4.922  
 €        
5.433  
 €        
5.944  
 €        
22.433  
 €        
27.033  
 €        
27.600  
 €        
27.600  
 €        
27.600  
 €        
27.600  
 Total 
 €        
862  
 €        
1.913  
 €        
2.424  
 €        
3.476  
 €        
5.082  
 €        
5.593  
 €        
6.644  
 €        
7.696  
 €        
8.207  
 €        
9.258  
 €        
10.864  
 €        
11.376  
 €        
41.967  
 €        
51.473  
 €        
52.040  
 €        
52.040  
 €        
52.040  
 €        
50.373  
     
Sales and 
Marketing              
Marketing 
expenses  
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
2.000  
 €        
800  
 €        
-    
 €        
1.000  
 €        
16.500  
 €        
500  
 €        
500  
 €        
1.300  
 €        
18.500  
 €        
1.700  
 €        
18.500  
 €        
1.700  
 €        
18.500  
 €        
11.700  
 Staff 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
15.000  
 €        
15.000  
 €        
48.000  
 €        
63.000  
 €        
78.000  
 €        
93.000  
Total 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
2.000  
 €        
800  
 €        
-    
 €        
1.000  
 €       
16.500  
 €        
500  
 €        
500  
 €        
1.300  
 €        
33.500  
 €        
16.700  
 €        
66.500  
 €        
64.700  
 €        
96.500  
 €        
104.700  
     
General 
Administration 
& Finance                                
Staff 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
54.000  
 €        
54.000  
 €        
72.000  
 €        
72.000  
 €        
72.000  




 €      
10.360  
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
3.000  
 €        
3.950  
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
3.000  
 €        
5.400  
 €        
3.000  
 €        
-    
 €        
3.000  
 €        
-    
 €        
3.000  
Utilities  
 €        
460  
 €        
460  
 €        
460  
 €        
460  
 €        
460  
 €        
460  
 €        
585  
 €        
585  
 €        
585  
 €        
585  
 €        
585  
 €        
585  
 €        
2.000  
 €        
2.000  
 €        
2.351  
 €        
2.651  
 €        
2.951  




 €        
2.900  
 €        
500  
 €        
500  
 €        
500  
 €        
500  
 €        
500  
 €        
3.050  
 €        
650  
 €        
650  
 €        
650  
 €        
650  
 €        
650  
 €        
4.650  
 €        
2.250  
 €        
3.780  
 €        
3.780  
 €        
3.780  
 €        
3.780  
Total 
 €      
13.720  
 €        
960  
 €        
960  
 €        
960  
 €        
960  
 €        
3.960  
 €        
7.585  
 €        
1.235  
 €        
1.235  
 €        
1.235  
 €        
1.235  
 €        
4.235  
 €        
66.050  
 €        
61.250  
 €        
78.131  
 €        
81.431  
 €        
78.731  
 €        
82.031  
     
Total 
Overhead  
 €      
14.582  
 €       
2.873  
 €       
3.384  
 €       
4.436  
 €        
8.042  
 €      
10.353  
 €      
14.529  
 €       
9.931  
 €      
26.242  
 €      
10.993  
 €        
12.899  
 €       
16.911  
 €        
152.717  
 €        
140.623  
 €        
207.871  
 €        
209.371  
 €        
238.721  
 €        
258.755  
                                   
EBITDA   
-€    
14.582  
-€       
2.873  
-€       
3.384  
 €       
1.564  
-€        
2.042  
-€       
4.353  
-€      
10.929  
 €       
19.569  
-€      
22.632  
-€       
7.383  
 €        
16.610  
 €       
12.608  
 €        
19.680  
 €        
118.040  
 €        
271.987  
 €        
416.464  
 €        
803.643  
 €        
816.557  
     
DEPR. & 
AMMORT. 
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
842  
 €        
842  
 €        
842  
 €        
883  
 €        
883  
 €        
883  
 €        
2.150  
 €        
2.150  
 €        
1.675  
 €        
1.800  
 €        
1.717  
 €        
1.967  
Total 
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
800  
 €        
842  
 €        
842  
 €        
842  
 €        
883  
 €        
883  
 €        
883  
 €        
2.150  
 €        
2.150  
 €        
1.675  
 €        
1.800  
 €        
1.717  
 €        
1.967  
     
EBIT   -15.382 -3.673 -4.184 764 -2.842 -5.153 -11.771 18.727 -23.474 -8.267 15.726 11.725 17.530 115.890 270.312 414.664 801.927 814.590 
      
annual 
aggregate -30.471     
annual 
aggregate 2.667  133.420  684.976  1.616.517 
       
INTERESTS      
     
 EBT    
-€    
15.382  
-€       
3.673  
-€       
4.184  
 €       
764  
-€        
2.842  
-€       
5.153  
-€      
11.771  
 €       
18.727  
-€      
23.474  
-€       
8.267  
 €        
15.726  
 €       
11.725  
 €        
17.530  
 €        
115.890  
 €        
270.312  
 €        
414.664  
 €        
801.927  
 €        
814.590  
     
Taxes      
Irap 
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
 €        
-    
Ires 
 €        
-    
 €        
-    
 €        
-    
 €        
229  
 €        
-    
 €        
-    
 €        
-    
 €        
5.618  
 €        
-    
 €        
-    
 €        
4.718  
 €        
3.517  
 €        
5.259  
 €        
34.767  
 €        
81.093  
 €        
124.399  
 €        
240.578  
 €        
244.377  
Total 
 €        
-    
 €        
-    
 €        
-    
 €        
229  
 €        
-    
 €        
-    
 €        
-    
 €        
5.618  
 €        
-    
 €        
-    
 €        
4.718  
 €        
3.517  
 €        
5.259  
 €        
34.767  
 €        
81.093  
 €        
124.399  
 €        
240.578  
 €        
244.377  
     
 NET 
INCOME    
-€    
15.382  
-€       
3.673  
-€       
4.184  
 €       
535  
-€        
2.842  
-€       
5.153  
-€      
11.771  
 €       
13.109  
-€      
23.474  
-€       
8.267  
 €        
11.008  
 €       
8.207  
 €        
12.271  
 €        
81.123  
 €        
189.218  
 €        
290.265  
 €        
561.349  







COST OF GOODS SOLD                      
                       
Full‐rate production costs per unit                      
Component  Quantity  Material cost  Machinery cost  Labour cost  Commercial price  Notes: B=Biomicron, 
Polycarbonate culture chamber with 2 1/4" x M333 fit holes for perfusion      1 € 1.400,00 € 224,00 € 214,00  € 1.838,00 B 
F=other 
suppliers 
Eccentric pliers for 2mm to 1mm thick scaffold made of Aisi 316L steel  2 € 800,00 € 188,00 € 196,00  € 1.184,00 B    
Culture chamber shaft coupling bellows made of medical grade silicone  2 € 212,00 € 14,00 € 54,00  € 280,00 B    
Top closed with screws incorporating 50mm petri dish with base suited to microscopic viewing, 
made of polycarbonate with aluminium inserts or sheet silicone with aluminium inserts   1 € 1.300,00 € 224,00 € 214,00  € 1.738,00 B    
50mm diameter petri dish   1          € 14,00 F    
Aluminium side covers for housing silicone bellows (cf. line 4)  2 € 95,00 € 224,00 € 214,00  € 533,00 B    
Shaft for connection of pliers and adapter for Parker motor made of Aisi 316L steel (connection 
ensured by an Allen screw and split pin)  1 € 95,00 € 112,00 € 106,00  € 313,00 B    
Shaft for connection of pliers and adapter for charging cell made of Aisi 316L steel (connection 
ensured by an Allen screw and split pin)  1 € 95,00 € 112,00 € 106,00  € 313,00 B    
Adapter for connection of drive shaft made of aluminium  1 € 54,00 € 46,00 € 106,00  € 206,00 B    
Extension for connection between drive shaft and actuator adapter made of aluminium   1 € 54,00 € 54,00 € 106,00  € 214,00 B    
Adapter for connection of shaft – charge cell made of aluminium  1 € 54,00 € 46,00 € 106,00  € 206,00 B    
Adapter for connection of cell and square guide for vertical translation of charge pliers made of 
aluminium   1 € 54,00 € 54,00 € 106,00  € 214,00 B    
Sigma koki commercial rack & pinion translators    1          € 253,00 F    
Igus square section runner  1          € 121,00 F    
Custom runner housing made of aluminium  1 € 13,00 € 46,00 € 106,00  € 165,00 B    
Connection between runner housing a custom translator made of aluminium  1 € 13,00 € 46,00 € 106,00  € 165,00 B    
Sigma koki commercial screw translators  2          € 31,00 F    
Connection between tank housing  1 € 14,00 € 46,00 € 214,00  € 274,00 B    
Custom translator made of aluminium  1 € 14,00 € 46,00 € 214,00  € 274,00 B    
Igus longitudinal positioning trolleys  2          € 113,00 F    
Custom adaptation plates made of aluminium  2 € 16,00 € 46,00 € 106,00  € 168,00 B    
Connection profile for Igus commercial positioning trolleys made of aluminium  1          € 91,00 F    
Auxiliary motor assembly plates made of aluminium  2 € 54,00 € 112,00 € 214,00  € 380,00 B    
Custom connection profiles made of aluminium  2 € 32,00 € 108,00 € 214,00  € 354,00 B    
Parker linear actuator complete with control driver and software  1          € 5.360,00 F    
xftc 300 50N charge cell complete with amplifier  1          € 990,00 F    
Case  1          € 212,00 F    
Packaging material   1   
Transport of 
components  Product transport  € 50,00 F    
Overall transport costs  N     € 90,00 € 50,00  € 140,00 F    
Installation and training  1          € 50,00 F    
      total material cost  total machinery cost  total labour cost  total comm. component cost       
      € 4.369,00 € 1.748,00 € 2.702,00  € 16.244,00      
            Cost to Biomicron Srl  € 8.819,00      
            Cost to other suppliers  € 7.425,00      
                       
Investments in research                      
   2 years     + VAT             
Work by entrepreneurs  70025 € 2.917,71     €                           2.900   month       
Materials  40444 € 5.055,50 6066,6  €                           6.070   per quarter       
Outside services  24231 € 3.028,88 3634,7  €                           3.650   per quarter       
                       
                       





this)                
Hourly cost of consulting for product upgrade 
 €                   
80,00   (no margin)                
Price of product development consulting 
 €                 






























Biomicron CED has drawn up a recruitment plan for the next five years, comprising the following figures 
with the relative costs: 
   Year 1  Year 2  Year 3  Year 4  Year 5 
CFO   €           ‐     €           ‐     €                  ‐     €   30.000,00    €   30.000,00 
CEO   €           ‐     €           ‐     €   20.000,00   €   20.000,00    €   20.000,00 
CTO   €           ‐     €           ‐     €   20.000,00   €   20.000,00    €   20.000,00 
CMO   €           ‐     €           ‐     €                  ‐     €   30.000,00    €   30.000,00 
COO   €           ‐     €           ‐     €   20.000,00   €   20.000,00    €   20.000,00 
Research undergraduates   €           ‐     €           ‐     €     7.500,00   €   15.000,00    €   15.000,00 
Assemblers and “production” operators   €           ‐     €           ‐     €   15.600,00   €   15.600,00    €   15.600,00 
Sales staff   €           ‐     €           ‐     €   20.500,00   €   39.000,00    €   83.500,00 
 
During the first two years of life of the company, all the work will be carried out by the three business 
partners, while from the third year onwards, the company will invest in production operators, research 
undergraduates and sales staff. The wages of the latter category will increase as time goes by, because its 
remuneration will consist of a fixed amount plus a variable amount linked to sales (2%) to offer an incentive 
to work as hard as possible. From the fourth year onwards, two more figures will join the company and they 
will be very important to the development of the business: they are the Chief Financial Officer and the Chief 
Marketing Officer. The company will assign them the task of strengthening the brand on the market and 




















    Balance Sheet 
    Time span – 5 years 
Euro    Year 1           Year 2           Year 3   Year 4   Year 5   























































 €            
115.345  
 €            
95.465  
 €            
85.305  
 €            
63.516  
 €            
29.956  
 €        
14.316  
 €      
105.460  
 €        
85.368  
 €        
55.905  
 €        
25.159  
 €        
41.105  
 €        
17.572  
 €      
102.361  
 €          
30.120  
 €          
22.864  
 €          
57.361  
 €        
195.474  
 €            
396.566  
Inventory  
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €             
-    
 €             
-    
 €          
14.370  
 €          
16.765  
 €          
23.950  




 €            
-    
 €            
-    
 €            
-    
 €            
7.680  
 €            
15.360  
 €        
23.040  
 €        
19.968  
 €        
64.896  
 €        
61.824  
 €        
61.824  
 €        
61.824  
 €      
109.824  
 €      
221.456  
 €        
399.344  
 €        
633.373  
 €        
922.256  
 €     
1.447.523  





 €          
115.345  
 €            
95.465  
 €            
85.305  
 €            
71.196  
 €            
45.316  
 €      
37.356  
 €    
125.428  
 €    
150.264  
 €    
117.729  
 €      
86.983  
 €    
102.929  
 €    
127.396  
 €    
323.817  
 €      
429.464  
 €      
670.607  
 €      
996.382  
 €   
1.666.947  
 €      
2.282.600  
 LONG TERM 
ASSETS  
Plant  
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €             
-    
 €             
-    
 €             
-    
 €               
-    
 €               
-    
 €               
-    
Machinery  
 €            
3.667  
 €            
3.333  
 €            
3.000  
 €            
2.667  
 €            
2.333  
 €         
2.000  
 €         
2.125  
 €         
1.750  
 €         
1.375  
 €         
1.458  
 €         
1.042  
 €            
625  
 €         
1.875  
 €            
1.125  
 €            
1.250  
 €            
1.250  
 €            
1.500  




 €            
2.900  
 €            
2.800  
 €            
2.700  
 €            
2.600  
 €            
2.500  
 €         
2.400  
 €         
2.300  
 €         
2.200  
 €         
2.100  
 €         
2.000  
 €         
1.900  
 €         
1.800  
 €         
1.500  
 €            
1.200  
 €            
2.700  
 €            
2.200  
 €            
1.700  
 €               
1.200  
Computers 
 €            
6.233  
 €            
5.867  
 €            
5.500  
 €            
5.133  
 €            
4.767  
 €         
4.400  
 €         
4.033  
 €         
3.667  
 €         
3.300  
 €         
2.933  
 €         
2.567  
 €         
2.200  
 €         
1.100  
 €             
-    
 €            
1.500  
 €            
1.200  
 €            
1.733  
 €               
1.267  
R&D 
 €            
14.658  
 €            
31.664  
 €            
38.440  
 €            
53.884  
 €            
77.722  
 €        
81.329  
 €        
93.604  
 €      
104.829  
 €      
105.822  
 €      
115.484  
 €      
133.540  
 €      
131.364  
 €      
136.438  
 €        
142.004  
 €        
137.004  
 €        
142.004  
 €        
137.004  




 €            
27.458  
 €            
43.664  
 €            
49.640  
 €            
64.284  
 €            
87.322  
 €      
90.129  
 €    
102.063  
 €    
112.446  
 €    
112.597  
 €    
121.876  
 €    
139.048  
 €    
135.989  
 €    
140.913  
 €      
144.329  
 €      
142.454  
 €      
146.654  
 €      
141.938  
 €         
137.638  
TOTAL ASSETS   
 €          
142.803  
 €          
139.130  
 €            
134.945  
 €            
135.481  
 €            
132.638  
 €    
127.485  
 €    
227.490  
 €    
262.709  
 €    
230.326  
 €    
208.859  
 €    
241.978  
 €    
263.385  
 €    
464.730  
 €       
573.793  
 €       
813.061  
 €   
1.143.036  
 €   
1.808.885  








 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €        
22.110  
 €        
13.200  
 €            
-    
 €        
22.110  
 €        
35.310  
 €        
42.680  
 €          
70.620  
 €        
120.670  
 €        
160.380  
 €        
264.880  








 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €      
22.110  
 €      
13.200  
 €            
-    
 €      
22.110  
 €      
35.310  
 €      
42.680  
 €        
70.620  
 €      
120.670  
 €      
160.380  
 €      
264.880  
 €         
306.020  
 LONG TERM 





 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €               
-    
 €               
-    
 €               
-    
Total 
Liabilities  
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €      
22.110  
 €      
13.200  
 €            
-    
 €      
22.110  
 €      
35.310  
 €      
42.680  
 €         
70.620  
 €       
120.670  
 €       
160.380  
 €       
264.880  




EQUITY   
Paid-in 
Capital 
 €            
10.000  
 €            
10.000  
 €            
10.000  
 €            
10.000  
 €            
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €        
10.000  
 €          
10.000  
 €          
10.000  
 €          
10.000  
 €          
10.000  




 €            
148.185  
 €            
148.185  
 €            
148.185  
 €            
148.185  
 €            
148.185  
 €      
148.185  
 €      
259.962  
 €      
259.962  
 €      
259.962  
 €      
259.962  
 €      
259.962  
 €      
259.962  
 €      
441.666  
 €        
441.666  
 €        
441.666  
 €        
441.666  
 €        
441.666  




-€            
15.382  
-€            
19.056  
-€            
23.240  
-€            
22.705  
-€            
25.547  
-€       
30.700  
-€       
42.472  
-€       
29.362  
-€       
52.836  
-€       
61.103  
-€       
50.094  
-€       
41.887  
-€       
29.615  
 €          
51.508  
 €        
240.726  
 €        
530.991  
 €     
1.092.339  





 €          
142.803  
 €          
139.130  
 €            
134.945  
 €            
135.481  
 €            
132.638  
 €    
127.485  
 €    
227.490  
 €    
240.599  
 €    
217.126  
 €    
208.859  
 €    
219.868  
 €    
228.075  
 €    
422.050  
 €      
503.173  
 €      
692.391  
 €      
982.656  
 €   
1.544.005  




SH EQUITY   
 €          
142.803  
 €          
139.130  
 €            
134.945  
 €            
135.481  
 €            
132.638  
 €    
127.485  
 €    
227.490  
 €    
262.709  
 €    
230.326  
 €    
208.859  
 €    
241.978  
 €    
263.385  
 €    
464.730  
 €       
573.793  
 €       
813.061  
 €   
1.143.036  
 €   
1.808.885  
 €       
2.420.238  
Check  
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €            
-    
 €             
-    
 €             
-    
 €             
-    
 €               
-    
 €               
-    
 €               








This category includes the following items: 
 Plant: this item has no value for Biomicron CED because, over the period of time envisaged, the 
company does not intend to purchase premises in which to pursue its activity, insofar as the 
registered office will be in Turin Polytechnic incubator I3P for the first three years, before moving to 
the premises of Biomicron Srl, where it will rent a room in which to pursue its activity.   
 Machinery: this item includes all the work instruments for the production of the bioreactor 
 Office Equipment: this item consists of the value of the furnishing of the premises where the 
company will operate. 
 Computers 
 R&D: this item comprises all the materials, labour and services that the company uses for research 
and development 
The estimated amortisation plan is as follows: 
 Machinery: 2 years 
 Office Equipment: 5 years 
 Computers: 3 years 
 R&D: 3 years 
The investment plan envisaged by CED, as well as the renewal of the equipment over the years due to 
obsolescence, is concentrated mainly on research and development; capital will be destined at the beginning 
of the activity and as soon as the company begins to issue invoices, thanks to sales, insofar as R&D is the 
key factor in this sector to continue being competitive on the market and to improve product performance. 
 
Current Assets 
The company’s current assets are 
 Customer Receivables: an average extension of customer payment terms will be between 90 and 120 
days, due to the presence of public departments, the bureaucratic times of which will undoubtedly 
extend the waiting time for payments.  
 Stock: evaluating that the time required to reorder materials is 6 weeks and developing the six-
monthly calculation (26 weeks), the average number of reorders that the company has to prudentially 
cover during a six-month period with stocks of components is 4.33; calculating the reorder demand 
with a ratio between the amounts sold and the coverage period and reaching an average, we have 
calculated the average stocks and their value, multiplied by the cost of the components  (7,185 €). 
 Cash and cash equivalents. 
 
Liabilities  have been calculated on the basis of extended payment terms of 60 days to outside suppliers and 
90 days for payment of the commercial partner Biomicron Srl. 
 
Shareholders Equity 
The items in this section are: 
 Shareholders’ equity: 10,000 € 
 Outside Investments 
 Profits reinvested. 
  
 CASH FLOW STATEMENT 
    Balance Sheet 
    Time span – 5 years 
Euro    Year 1           Year 2           Year 3   Year 4   Year 5   






















































 Cash flow from Operations:  
 Net Income  
-€           
15.382  
-€           
3.673  
-€         
4.184  
 €           
535  -€           2.842  
-€           
5.153  
-€          
11.771  
 €        
13.109  
-€          
23.474  
-€           
8.267  
 €         
11.008  
 €          
8.207  
 €            
12.271  
 €          
81.123  
 €        
189.218  
 €        
290.265  
 €      
561.349  
 €         
570.213
 cumulated  
















 €       
1.131.5
 Depreciation and Amortization  
 €            
1.662  
 €           
2.713  
 €         
3.224  
 €           
4.276   €           5.882  
 €           
6.393  
 €            
7.486  
 €          
8.537  
 €           
9.048  
 €         
10.141  
 €         
11.748  
 €        
12.259  
 €            
44.117  
 €          
53.623  
 €          
53.715  
 €         
53.840  
 €        
53.757  
 €         
52.340 
 cumulated  
















 €         
106.097
 Change in Working Capital  
 €            
-    
 €           
-    
 €           
-    
 €           
7.680   €           7.680  
 €           
7.680  
-€            
3.072  
 €        
22.818  
 €           
5.838  
 €         
13.200  
-€         
22.110  
 €        
34.800  
 €          
104.262  
 €        
149.948  
 €        
198.349  
 €        
251.568  
 €      
427.952  
 €         
373.421
cumulated 
















 €         
801.373
 Net cash provided/(used) by operating 
activities:  
-€ 
13.720 -€ 960 -€ 960 
-€ 











 €        
44.866  
-€ 
14.334 -€ 47.874 
-€ 






-€         
29.589  cumulated 












 €         
436.285
 Cash flow from Investments:  
 Purchase of equipment  29.120 18.920 9.200 18.920 28.920 9.200 19.420 18.920 9.200 19.420 28.920 9.200 49.040 57.040 51.840 58.040 49.040 48.0



















19.420 -€ 28.920 
-€ 
9.200 -€ 49.040 
-€ 
57.040 -€ 51.840 
-€ 
58.040 -€ 49.040 48.04
cumulated 
















-€        
97.080 



















30.745 € 15.946 
-€ 
23.534 -€ 96.914 
-€ 






















 €         
339.205




















































30.745 -€ 14.799 
-€ 
38.333 -€ 96.914 
-€ 













38.333 -€ 96.914 
-€ 



































 Cash flow from financing:  
 Equity investment  
 €           
10.000  
 External Financing  






 Net cash provided/(used) by financing 
activities:  
 €        
158.185  
 €           
-    
 €           
-    
 €           
-     €               -    
 €            
-    
 €       
111.776  
 €            
-    
 €            
-    
 €            
-    
 €              
-    
 €            
-    
 €        
181.704  
 €            
-    
 €              
-    
 €            
-    
 €             
-    
 €        
-    
cumulated 












 €            
-    
 
cumulated  
 €         
-    
 Final Net Cash Flows  
 €        
115.345  
-€       
19.880  
-€      
10.160  
-€        
21.789  -€       33.560  
-€       
15.640  
 €         
91.143  
-€      
20.092  
-€        
29.463  
-€       
30.745  
 €        
15.946  
-€      
23.534  
 €          
84.790  
-€        
72.242  
-€          
7.256  
 €        
34.497  
 €     
138.113  
 €        
201.09
cumulated 
















 €         
339.205
 Beginning Cash Balance  
 €            
-    
 €        
115.345  
 €       
95.465  
 €          
85.305   €         63.516  
 €         
29.956  
 €           
14.316  
 €       
105.460  
 €          
85.368  
 €         
55.905  
 €         
25.159  
 €        
41.105  
 €            
17.572  
 €        
102.361  
 €          
30.120  
 €         
22.864  
 €        
57.361  





 €          
115.345  
-€         
19.880  
-€       
10.160  
-€          
21.789  -€         33.560  
-€         
15.640  
 €           
91.143  
-€        
20.092  
-€          
29.463  
-€         
30.745  
 €         
15.946  
-€        
23.534  
 €            
84.790  
-€          
72.242  
-€           
7.256  
 €         
34.497  
 €      
138.113  
 €         
201.092
 Ending Cash Balance  
 €          
115.345  
 €         
95.465  
 €       
85.305  
 €          
63.516   €         29.956  
 €         
14.316  
 €         
105.460  
 €        
85.368  
 €          
55.905  
 €         
25.159  
 €         
41.105  
 €        
17.572  
 €          
102.361  
 €          
30.120  
 €          
22.864  
 €         
57.361  
 €      
195.474  
 €         
396.566
Cash Risk 
 Annual cash flows  Year 1  Year 2  Year 3  Year 4  Year 5 
-              
143.869  
-            
108.521  
-              
169.156  
                
27.241  
            
339.205 
-€             
143.869  
-€          
108.521  
-€        
169.156  
 €            





Annual cash flows  
Year 1 Year 2 Year 3 Year 4 Year 5  
Poly (Annual Cash flows)
